City of Birmingham Mayor's Office ’s Post

Biotech’s public policy pillars are crumbling. Without a meaningful change in public support, biomedical innovation will slow. Companies and investors must do more to convince policymakers the biopharma industry is a treasure worth nurturing. An editor's commentary by BioCentury Inc.'s Steve Usdin.

🌱 Growing the UK Life Sciences 🔬 Dr Stella Peace, Executive Director of Healthy Living and Agriculture at Innovate UK, joins entrepreneurs, investors, and industry leaders at the 2024 Life Sciences Summit in Aberdeen. 🚀 In her keynote address, Stella highlights Innovate UK's commitment to inspiring, involving, and investing in innovation, particularly in bridging the gap between inception and commercialisation. Key pillars include: 💡 Power of Patience: Long-term investment in businesses, including £300M through the Biomedical Catalyst programme and the Bio-based Manufacturing Launchpad. 🏢 Power of Place: Support for innovation clusters across the UK, including the world-leading Cell and Gene Therapy Catapult in Edinburgh and Medicines Manufacturing Innovation Centre in Glasgow/Renfrewshire. 🤝 Power of Partnerships: Importance of local partnerships for accelerating regional growth, exemplified by initiatives like the Glasgow City Region Local Action Plan and MOU with Scottish Enterprise. 👥 Power of People: Securing the future pipeline of skills and talent in life sciences through programmes like Future Leaders Fellowships, Talent and Skills Connect, and No Limits. Life Sciences is critical for the UK's global impact, driven by innovation. Innovate UK is dedicated to advancing business innovation in life sciences, paving the way for longer, healthier lives. Our initiatives, including the Biomedical Catalyst programme, Transforming Medicines Manufacturing, and our today announced involvement in the Dame Barbara Windsor Dementia Mission, are tailored to bolster the life sciences industry, providing essential support for talent acquisition, growth, scaling, and more. Learn more about our work supporting Life Sciences businesses: https://ow.ly/AA6m50QXUwz #LifeSciences #Innovation #BusinessInnovation The Times

🔬 Are you a passionate scientist actively involved in groundbreaking research but unsure how to turn your projects into reality? We are excited to announce a partnership between #INSIGHT2023 and Negev Labs where Matthew W. Johnson, Ken Belotsky, Kostia Adamsky, and Hayim Raclaw will be hosting 'From Concept to Funding & Development: A Negev Labs Psychedelic Drug Discovery and Development Platform.' This session serves as a stepping stone for the next generation of neuro-innovators, providing you with the access, resources, and network necessary to transform your research projects into realities. Learn from the experts at Negev Labs and gain insights into their investment philosophy and selection criteria for early-stage funding in the biotech sector. To celebrate this partnership, all scientists actively engaged in research can purchase a limited number of 30% discounted INSIGHT 2023 conference tickets using the 🎟️ #NEGEVDISCOUNT 🎟️ code. Together, let us build a community of neuro-innovators and investors committed to transforming scientific discoveries into life-changing therapies. #MINDFoundation #NeuroInnovators #Biotech #ScienceCommunity 

Wrapping up three dynamic days at Biotechnology Innovation Organization annual convention in San Diego, where we released Cure.’s inaugural biotech benchmark report, Ready, Set, Growth! Cure, an affiliate of Deerfield Management, conducted this highly anticipated assessment of the #biotech industry in partnership with the Deerfield Institute, a division of Deerfield Management. The survey included company #founders and #CEOs, #managing directors, #investors, #scientists, and more. Exciting insights from experts in the field revealed an overwhelming sense of #hope and #optimism across the biotech sector, with 79 percent of individuals betting on growth. Advances in #science and investment opportunities in areas like #neurology, #metabolicdisease, and #oncology, driven by cutting-edge technologies such as #cell and #genetherapies and #AI and #machinelearning are fueling this positivity. Despite progress in various key areas, the survey highlighted a significant lack of innovation and investment in #womenshealth. Nearly 65 percent of respondents expressed #support for more #investment in women’s health. This trend is encouraging, as increased attention and #government funds are now being directed towards women's health, paving the way for potential industry #growth and resurgence. The much-needed investment in #womenfounders and women's health could be the cornerstone for the biotech #comeback and expansion. While it’s hard to know if the trend lasts, nurturing the growth of women's health initiatives could be the #catalyst for the industry #turnaround we aspire to see. Thanks to Caroline D. Marion E. Glick Daniel Glass William Cheung Anna Howell Leah Rosenbaum Cedric Beckles Ben Green Leah Rosenbaum Paul Oestreicher Elizabeth Rose Hansen Rosie Zaloum Foster Dan Hoffman Lauren Ruotolo David Duncan for a terrific report and the ground team who brought everything to life including Caroline D. Susanna Ling Vilia Baumilas Alana Elliott and our new COO Charles Kim. Plus thanks to David Greenwald, Ph.D. Mary Stutts, MHA Jamie Metzl David Fajgenbaum, MD, MBA, MSc Grant W Mitchell, MD, MBA Brittany Connors, PMP Stephanie Fertig Matthew Portnoy Raheleh H. To read the report go to www.wewillcure.com Finishing up the morning with a panel on De-risking drug development with Wyatt Gotbetter Gotbetter Ned Wydysh Susan Billings, Ph.D. Dan Gold Abhiram Rao, PhD Parexel #BIO2024 #wewillcure

Regarding the latest breakthroughs and innovations in the health tech sector, Smart In Media is always a competent contact. CMO Martin Weihrauch, M. D. and General Manager USA Don VAN DYKE are sharing insight into our recipes for success and future strategies this week in California at the invitation of the Chamber of Commerce. In the heart of the largest biotech hub on the US West Coast, the two will meet #entrepreneurs, #investors and representatives of #universities. They will also discuss what contribution German companies like Smart In Media can make to improve the overarching landscape of biotech development in Silicon Valley. One of the trip's highlights is today's Transatlantic Medical Biotech Symposium in San Francisco. Participants from different business sectors will discuss how Medical Biotechnology is Advancing Modern Healthcare between the US and Germany. Martin and Don will present the Smart In Media concept for enhancing Digital Pathology in this course. Here is a little spoiler on the takeaways: 👉 How AI and Big Data can be used to gain new approaches to manufacturing and developing drugs and treatments 👉 How to maintain a balance between innovation and ethical considerations to ensure patient well-being and create a robust regulatory framework that fosters responsible innovation 👉 How the close coordination of research institutions and the futuristic atmosphere of Silicon Valley enables faster and more efficient development of life-saving medical care The Transatlantic Medical Biotech Symposium aims to foster meaningful partnerships and knowledge exchange between the vibrant biotechnology communities in #California and #Germany. GACC WEST - Representative of German Business invited us to this business week in the course of the program "Mittelstand Global – Markterschließungsprogramm für KMU“. To kick things off, we have already met the other program participants: ASP Lab Automation AG, Bundesverband der Pharmazeutischen Industrie, Axolabs GmbH, Vivlion GmbH, easyRadiology and Anteris Medical #TransatlanticBiotech #biotech #healthcare #digitapathology #vc ##IoTHealthcare

Whilst the idea of fractional consulting appears to be an obvious concept, we are often asked to explain how we have applied this flexible approach with our clients. A great example is Cellestial Health, which is a start-up Biotech based in Cambridge created and led by CEO Nataly H. Nataly’s translational research focusses on the importance of protecting networks of brain cells called astrocytes. They play a role in inflammatory brain conditions, including Parkinson's, for which no cure or disease-modifying therapy currently exists. This is fundamentally different from the traditional neurone-centred paradigms, which can open up previously overlooked opportunities. Nataly created Cellestial Health which she spun off from her academic work. Setting up a small but dynamic biotech required many new skills, which is where phraktion offered support, including preclinical support provided by Paul Ford. Paul was instrumental in helping Nataly devise a strong strategy, alongside phraktion who were able to facilitate access to a wider network of experts. Their experience offered up useful advice on a variety of topics such as IP. With preclinical studies underway and new investor contacts established, Nataly is now looking forward to bringing innovative solutions to a difficult-to-target disease space like Parkinson's.  Cellestial is currently looking to close its Pre-Seed funding round, so if you would like to get involved with Cellestial Health, Nataly H. would love to hear from you! If you are a similar small but aspiring biotech needing help to move your ideas forward, Paul Ford, and all of the Co-founders at phraktion would love to hear from you! Bruce, Paul, Gordon, Nigel #Biotech #Pharma #MedTech #fractional #consulting

Better healthcare starts here: The University of Ottawa’s new Advanced Medical Research Centre (AMRC) will play a crucial role in curbing Ottawa’s biotech brain drain. Ottawa has earned its global reputation as a vibrant city for medical research and innovation. But if it wants to keep its top researchers in the region and build a thriving biotech sector, more lab space and private investment will be needed, says Jean-Simon Diallo, who is founder and CEO of Virica Biotech Inc, scientist at the Ottawa Hospital Research Institute, and associate professor at the uOttawa | Faculté de médecine | Faculty of Medicine. At the Advanced Medical Research Centre (AMRC), researchers, health-care professionals and investors will team up to accelerate the discovery and commercialization of life-saving therapies.  “The AMRC is a good example of the understanding that we need to get researchers to commercialize their intellectual property. But we also need to support them with the space and the equipment they need.” says Dane Bedward, CEO of NeuroBot Inc. and former senior vice president international for Genzyme Corporation. “There’s so much grey matter here, but so many inventions that have come out of Canada get gobbled up and taken outside Canada.” Read the article or watch the video to learn more about how the AMRC will provide huge opportunities for the next wave of Ottawa biotech researchers and entrepreneurs. - https://lnkd.in/g46-G9Au #uOttawa #uOttawaAMRC #BetterHealthcare #StartsHere #Ottawa #research #biotech

++Unmute++ $213,000,000... it's a lot of zeros. And if someone in the region won the lottery for that amount, you'd expect to hear about it. Someone did... three weeks ago... Well, not someone but one company. Landos Biopharma, Inc. which is based in Blacksburg and was bought for that amount by the international pharmaceutical company AbbVie. Unless you subscribe to bio-tech trade press or PR News Wire you'd never know that tech companies in our region were valued anywhere near that amount. Leading that quiet change in the Central and Southwest Virginia economy is Virginia Bio. On this edition of Virginia Technology Today we speak to CEO John Newby. He paints a picture of a vibrant ecosystem that's been growing steadily for nearly three decades. Newby's insights into the biotech sector are eye-opening. He discusses the critical role that startups play, many of which are spun out of research institutions like Virginia Tech with the support if institutions like Fralin Biomedical Research Institute at VTC, Verge (formerly Valleys Innovation Council), Carilion Clinic and many others. These companies are not just improving lives; they're saving them by transforming cutting-edge research into accessible treatments. But perhaps the most compelling part of the story is the shift from what Newby refers to as a "train city to a brain city." This transition is not just about economic change; it's about the power of knowledge and innovation to redefine an area's identity and potential. So, if you're curious about the future of health, the power of research, and the economic potential of biotech, tune in to this episode. It's a narrative of hope, ambition, and the relentless human spirit driving Virginia's biotech industry forward. Listen now and be part of the conversation that's changing the world, one discovery at a time. A special thanks to: Caron Trumbo, John S. Phillips, Kimberly Blair, Bill Trifiro, Michael Friedlander, Virginia Tech Carilion School of Medicine, Virginia Coordinated Clinical Research Network (VCCRN),

Very interesting and helpful for many people.

It is fantastic to be back in Switzerland on my way from Zürch to Basel🇨🇭. This is Moa Persson and my second trip down here in a couple of months and the reason is that things are just happening here! The biotech sector seems to be exploding all over this region, with both mastodons of the medical world being here, but also a vast and flourishing ecosystem of smaller start-up's as well as exciting research being done at Universities. This is just the place for Symcel to be and from our meetings with academics and companies, we have a platform that is a perfect fit for this ecosystem! So much work is being done into the research of new #antimicrobials, #phages, and #celltherapy, that our solutions for complex in-vivo-like model systems as well as fast and sensitive detection of bacteria are a perfect match. This will not be our last trip down here! We are ready for so much more synergy with these amazing clusters of #biotechnologyindustry